Show simple item record

dc.contributor.authorMartínez García, Elena
dc.contributor.authorLesur, Antoine
dc.contributor.authorDevis, Laura
dc.contributor.authorRosa Campos, Alexandre
dc.contributor.authorCabrera, Silvia
dc.contributor.authorOostrum, Jan van
dc.contributor.authorMatias-Guiu, Xavier
dc.contributor.authorGil-Moreno, Antonio
dc.contributor.authorReventós, Jaume
dc.contributor.authorColás, Eva
dc.contributor.authorDomon, Bruno
dc.date.accessioned2016-09-14T08:00:50Z
dc.date.available2016-09-14T08:00:50Z
dc.date.issued2016
dc.identifier.issn1949-2553
dc.identifier.urihttp://hdl.handle.net/10459.1/57799
dc.description.abstractAbout 30% of endometrial cancer (EC) patients are diagnosed at an advanced stage of the disease, which is associated with a drastic decrease in the 5-year survival rate. The identification of biomarkers in uterine aspirate samples, which are collected by a minimally invasive procedure, would improve early diagnosis of EC. We present a sequential workflow to select from a list of potential EC biomarkers, those which are the most promising to enter a validation study. After the elimination of confounding contributions by residual blood proteins, 52 potential biomarkers were analyzed in uterine aspirates from 20 EC patients and 18 non-EC controls by a high-resolution accurate mass spectrometer operated in parallel reaction monitoring mode. The differential abundance of 26 biomarkers was observed, and among them ten proteins showed a high sensitivity and specificity (AUC > 0.9). The study demonstrates that uterine aspirates are valuable samples for EC protein biomarkers screening. It also illustrates the importance of a biomarker verification phase to fill the gap between discovery and validation studies and highlights the benefits of high resolution mass spectrometry for this purpose. The proteins verified in this study have an increased likelihood to become a clinical assay after a subsequent validation phase.ca_ES
dc.description.sponsorshipThis work was supported by the Spanish Ministry of Health (RD12/0036/0035), the Spanish Ministry of www.impactjournals.com/oncotarget 53114 Oncotarget Economy and Competitivity (PI14/02043; Juan de la Cierva -Formación grant FPDI-2013-18322 grant to EC), the FPU grant from the Spanish Ministry of Education, Culture and Sport (AP2012-5571 grant to EM); “Fondo Europeo de Desarrollo Regional” FEDER (RTC-2014- 3110-1), the AECC (Grupos Estables de Investigacion 2011 - AECC- GCB 110333 REVE), the Fundació La Marató TV3 (2/C/2013), the CIRIT Generalitat de Catalunya (2014 SGR 1330) and the European Commission, 7th Framework Programe, IRSES (PROTBIOFLUID –269285) – Belgium. The present work has been also funded by the "Fonds National de la Recherche du Luxembourg" (FNR) via the PEARL-CPIL program to BD, and an AFR grant to AL (PDR 2013-2, Project Reference 6835664).ca_ES
dc.language.isoengca_ES
dc.publisherImpact Journalsca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.18632/oncotarget.10632ca_ES
dc.relation.ispartofOncotarget, 2016, vol. 7, núm. 33, p. 53102-53115ca_ES
dc.rightscc-by, (c) Impact Journals, 2016ca_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectUterine aspirateca_ES
dc.subjectEndometrial cancerca_ES
dc.subjectBiomarker verificationca_ES
dc.subjectHigh resolution accurate mass spectrometryca_ES
dc.subjectParallel reaction monitoringca_ES
dc.titleDevelopment of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samplesca_ES
dc.typearticleca_ES
dc.type.versionpublishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.18632/oncotarget.10632
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/269285ca_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

cc-by, (c) Impact Journals, 2016
Except where otherwise noted, this item's license is described as cc-by, (c) Impact Journals, 2016